Transplantation Infection
Conditions
Keywords
Stem Cell Transplant, Hemorrhagic Cystitis, Bladder inflammation, Frequent urination, Pain, Polyomavirus hominis type I, BK virus, BKV, Cidofovir, Vistide
Brief summary
The goal of this clinical research study is to learn if adding cidofovir to the standard of care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to standard of care alone. The safety of cidofovir will also be studied.
Detailed description
The Study Drug: Cidofovir is an anti-viral drug that is designed to treat or prevent infections caused by certain kinds of viruses. Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups and you will have an equal chance of being in either group: * If you are in Group 1, you will receive standard of care drugs and cidofovir. The doctor will tell you more about the standard of care drugs that you will take and the risks for them. * If you are in Group 2, you will only receive standard of care drugs. Study Drug Administration: If you are in Group 1, you will receive cidofovir by vein over about 1 hour 3 times per week. You will also receive standard of care, which may include oral pain drugs taken every 4 to 6 hours as needed, oral drugs for urinary urgency taken 2 times daily, and fluids given by vein to increase your urination rate. If you are in Group 2, you will only receive the standard of care, as described above. Study Visits: Each week: * Blood (about 2 tablespoons) will be drawn for routine tests. * You will have a physical exam, including measurement of your vital signs. Every 2 weeks, you will complete the questionnaire about urinary problems. Length of Study: If you are in Group 1, you may continue taking the study drug for up to 4 weeks. Group 2 will take the standard of care for 4 weeks. If the doctor thinks it is needed Groups 1 and 2 can continue to receive standard of care after this study is over. If your symptoms get worse during the study and you are not receiving cidofovir, you may be eligible for further treatments, which may include cidofovir, after the study ends. You will no longer be able to take the study drug if the disease gets worse or intolerable side effects occur. Your participation on the study will be over once you have completed the end-of-treatment visit and the follow-up visit. End-of-Treatment Visit: After you finish treatment: * Urine will be collected to test the level of BK virus. * You will complete the questionnaire about urinary problems. Follow-up Visit: Four (4) weeks after treatment ends: * You will have a physical exam, including measurement of your vital signs. * Urine will be collected to test the level of BK virus. This is an investigational study. Cidofovir is FDA approved and commercially available for the treatment of several viral infections. Its use in patients with the BK virus after a stem cell transplant is investigational. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
DRUGCidofovir
0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
OTHERNo Cidofovir
Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. HSCT patients with symptomatic hemorrhagic cystitis (minimal Grade 1 symptoms of HC per NCI criteria) and positive BKV in urine \>1x103 DNA copies/ml 2. Age \>/= 6 years 3. Patient must sign the informed consent document.
Exclusion criteria
1. Creatine clearance \< 55 ml/min, calculated using ideal body weight (IBW) using Cockcroft-Gault equation 2. Concomitant use of foscarnet, liposomal amphotericin B or aminoglycoside 3. Use of cidofovir for bladder instillation 4. Use of formalin or hyperbaric oxygen treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients with Microbiologic Response | 8 weeks | Response defined as improvement in symptoms based on questionnaire, reduction or stability in grade of hemorrhagic cystitis, and level of virus must be a 1 log reduction from baseline when the BKV was first diagnosed. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORBorje S. Andersson, MD,PHD
M.D. Anderson Cancer Center
Outcome results
None listed